Senti Biosciences Inc (SNTI) - Net Assets
Based on the latest financial reports, Senti Biosciences Inc (SNTI) has net assets worth $8.12 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($52.69 Million) and total liabilities ($44.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SNTI financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.12 Million |
| % of Total Assets | 15.41% |
| Annual Growth Rate | 7.38% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 197.05 |
Senti Biosciences Inc - Net Assets Trend (2019–2024)
This chart illustrates how Senti Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Also explore SNTI current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Senti Biosciences Inc (2019–2024)
The table below shows the annual net assets of Senti Biosciences Inc from 2019 to 2024. For live valuation and market cap data, see SNTI company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $25.65 Million | -61.67% |
| 2023-12-31 | $66.91 Million | -47.42% |
| 2022-12-31 | $127.26 Million | +110.78% |
| 2021-12-31 | $60.38 Million | +202.83% |
| 2020-12-31 | $-58.71 Million | -426.82% |
| 2019-12-31 | $17.96 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Senti Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25723900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Components | $322.78 Million | 1258.46% |
| Total Equity | $25.65 Million | 100.00% |
Senti Biosciences Inc Competitors by Market Cap
The table below lists competitors of Senti Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
exax Inc
KQ:060230
|
$21.88 Million |
|
Antec Inc
TWO:6276
|
$21.88 Million |
|
Only World Group Holdings Bhd
KLSE:5260
|
$21.89 Million |
|
Zodiac Clothing Company Limited
NSE:ZODIACLOTH
|
$21.89 Million |
|
Aroot Co. Ltd
KQ:096690
|
$21.86 Million |
|
Sejoong Co. Ltd
KQ:039310
|
$21.86 Million |
|
Mida Assets Public Company Limited
BK:MIDA
|
$21.85 Million |
|
Leyand International Tbk
JK:LAPD
|
$21.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Senti Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 66,913,000 to 25,649,000, a change of -41,264,000 (-61.7%).
- Net loss of 52,790,000 reduced equity.
- New share issuances of 49,059,000 increased equity.
- Other comprehensive income increased equity by 119,484,000.
- Other factors decreased equity by 157,017,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-52.79 Million | -205.82% |
| Share Issuances | $49.06 Million | +191.27% |
| Other Comprehensive Income | $119.48 Million | +465.84% |
| Other Changes | $-157.02 Million | -612.18% |
| Total Change | $- | -61.67% |
Book Value vs Market Value Analysis
This analysis compares Senti Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.18x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.08x to 0.18x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $13.22 | $1.02 | x |
| 2020-12-31 | $-13.45 | $1.02 | x |
| 2021-12-31 | $13.83 | $1.02 | x |
| 2022-12-31 | $28.96 | $1.02 | x |
| 2023-12-31 | $15.08 | $1.02 | x |
| 2024-12-31 | $5.58 | $1.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Senti Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -205.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 3.81x
- Recent ROE (-205.82%) is below the historical average (-92.90%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -117.77% | -24890.59% | 0.00x | 2.00x | $-22.95 Million |
| 2020 | 0.00% | -5041.12% | 0.01x | 0.00x | $-13.99 Million |
| 2021 | -91.62% | -2414.62% | 0.02x | 1.60x | $-61.36 Million |
| 2022 | -35.98% | -1068.39% | 0.02x | 1.42x | $-58.52 Million |
| 2023 | -106.19% | -3592.42% | 0.02x | 1.79x | $-77.75 Million |
| 2024 | -205.82% | 0.00% | 0.00x | 3.81x | $-55.35 Million |
Industry Comparison
This section compares Senti Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Senti Biosciences Inc (SNTI) | $8.12 Million | -117.77% | 5.49x | $21.87 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Senti Biosciences Inc
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications w… Read more